Drug Profile
Research programme: rhinovirus therapeutic - Alios BioPharma
Alternative Names: Rhinovirus nuc inhibitorLatest Information Update: 28 May 2018
Price :
$50
*
At a glance
- Originator Alios BioPharma
- Class Nucleosides
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Rhinovirus infections
Most Recent Events
- 28 May 2018 No recent reports of development identified for preclinical development in Rhinovirus-infections in USA
- 07 Nov 2014 Alios BioPharma has been acquired by Johnson & Johnson
- 07 Apr 2014 Preclinical trials in Rhinovirus infections in USA (unspecified route)